Annual Completed Clinical Trials Report

The growth of completed trials activity in 2023 reflects broad increases across most therapeutic areas, and a clear break from pandemic period fluctuations observed since 2020. In addition to broad-based completed trials growth in 2023, trial success rates improved year over year, another reflection of how the challenges of the pandemic years are no longer driving trends in 2023.

First Name *

Last Name *

Company *

Job Title *

Department

Business Email Address *

Country *

Business Phone *

How Can We Help

fieldlabel

Citeline may contact you about relevant products, services, and content. To opt out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.

Related resources

MAY 09, 2024

Infographic

Clinical

Pharma Annual R&D Review 2024 Supplement Infographic: New Active Substances Launched During 2023

Highlights from the Pharma R&D Review 2024 Supplement, a look at new active substances (NASs), drugs launched onto the market for the first time, in 2024.

APR 08, 2024

Report

Commercial

Q2 2024 Outlook Report

Discover the catalysts, deals and likelihood of approval for 22 key drugs, devices and diagnostics expected to occur in Q2 2024.

MAR 28, 2024

White paper

Commercial

2023 Deal-making Roundup

An overview of alliance, M&A, and financing deal activity across the
worldwide biopharma, medical device, and in vitro diagnostics
industries in 2023